September 2, 2026
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Corporate Overview
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a late-clinical stage gamma secretase inhibitor for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand which recently received IND clearance. Our preclinical pipeline includes IM-1617, IM-1340, and IM-1335, all of which are ADCs pursuing undisclosed targets with expression in multiple solid tumors.
Latest Presentation
Latest Event
09/14/2026
H.C. Wainwright 28th Annual Global Investment Conference at 11:00a.m.
WebcastView All Events